Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTN

Award Number: UM1CA186717
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/28/2014
PERIOD OF PERFORMANCE END DATE: 02/28/2027

Group Awards By:

View Award Description

Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTN - PROJECT SUMMARY As the California Cancer Consortium (CCC), four National Cancer Institute (NCI)-Designated Cancer Centers propose to participate in the NCI Experimental Therapeutics Clinical Trials Network (ETCTN) to conduct early phase clinical trials of experimental therapeutics. The CCC comprises City of Hope (COH, Lead Academic Organization [LAO]), the University of Southern California (USC, Affiliated Organization [AO]), the University of California, Davis (UCD, AO), and Stanford Cancer Institute (SCI, AO), and has a 25-year history as a multidisciplinary group conducting early phase clinical trials of NCI-sponsored investigational new drugs under previous U01 and UM1 Cooperative Agreements and N01 Contracts. Our multidisciplinary group of investigators will contribute to ETCTN Project Teams by leveraging the combined expertise of COH, UCD, USC, and SCI in molecular pharmacology, pharmacokinetics, pharmacodynamics, pharmacogenomics, signal transduction, cell cycle regulation, non-invasive imaging, and bioinformatics to conduct innovative, laboratory-directed early phase developmental and pharmacokinetic studies. We propose to use the combined patient and scientific resources and expertise of UCD, COH, USC, and SCI to accomplish the following Specific Aims: (Aim 1) to use the existing relevant capabilities and scientific leadership of the CCC to enhance the ETCTN program; (Aim 2) to leverage the combined breadth of the clinical programs at COH, USC, UCD, and SCI NCI-Designated Comprehensive Cancer Centers to support the rapid completion of ETCTN trials; (Aim 3) to use the central Data Coordinating Center (DCC) and Biostatistics Core (BC) at COH to facilitate frequent communication within the CCC and with the NCI and ETCTN, provide rapid development and effective oversight of trials, and ensure adherence to policies and procedures; and (Aim 4) to optimize information gained from ETCTN clinical trials by including molecular characterization of patients’ malignancies and incorporating molecular pharmacodynamic endpoints and investigational imaging. These early phase studies will lead to recommended, biologically effective doses, greater understanding of the spectrum of normal tissue toxicity of agents, and initial estimates of efficacy. They will also provide mechanistic validation of the effects of the agents on critical tumor cell targets, correlate drug-related changes in tumor and host biologic markers with clinical outcome, and develop new insights into the therapeutic mechanisms of action of the compounds both in the laboratory and the clinic. As such, they will advance the ETCTN’s overall goal of accelerating the development of novel anticancer agents that capitalize on unique molecular features of individual tumors and identifying appropriate biomarkers to select patients who are most likely to respond to specific agents.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2025	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	1500 DUARTE RD	DUARTE	CA	91010	LOS ANGELES	USA	Cancer Treatment Research	000	9	2/27/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $1,903,401 )
2025	2025	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	1500 DUARTE RD	DUARTE	CA	91010	LOS ANGELES	USA	Cancer Treatment Research	002	9	5/28/2025	NON-COMPETING CONTINUATION	$190,341
2025	2025	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	1500 DUARTE RD	DUARTE	CA	91010	LOS ANGELES	USA	Cancer Treatment Research	001	9	4/21/2025	NON-COMPETING CONTINUATION	$1,713,060
2025	2024	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	1500 DUARTE RD	DUARTE	CA	91010	LOS ANGELES	USA	Cancer Treatment Research	000	8	12/31/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $1,903,401

Issue Date FY: 2024 ( Subtotal = $1,293,587 )
2024	2024	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	1500 DUARTE RD	DUARTE	CA	91010	LOS ANGELES	USA	Cancer Treatment Research	003	8	4/15/2024	NON-COMPETING CONTINUATION	$1,293,587
2024	2024	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	1500 DUARTE RD	DUARTE	CA	91010	LOS ANGELES	USA	Cancer Treatment Research	004	8	7/16/2024	NON-COMPETING CONTINUATION	$0
2024	2023	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	1500 DUARTE RD	DUARTE	CA	91010	LOS ANGELES	USA	Cancer Treatment Research	002	7	3/13/2024	EXTENSION WITH OR WITHOUT FUNDS	$781,405
2024	2020	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	1500 DUARTE RD	DUARTE	CA	91010	LOS ANGELES	USA	Cancer Treatment Research	000	6	3/13/2024	COMPETING CONTINUATION	-$574,005
2024	2020	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	1500 DUARTE RD	DUARTE	CA	91010	LOS ANGELES	USA	Cancer Treatment Research	001	6	3/13/2024	SUPPLEMENT FOR EXPANSION	-$207,400
														Subtotal = $1,293,587

Issue Date FY: 2023 ( Subtotal = $1,594,203 )
2023	2023	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	1500 DUARTE RD	DUARTE	CA	91010	LOS ANGELES	USA	Cancer Treatment Research	000	7	6/29/2023	EXTENSION WITH OR WITHOUT FUNDS	$1,594,203
														Subtotal = $1,594,203

Issue Date FY: 2022 ( Subtotal = $11,360 )
2022	2019	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	1500 DUARTE RD	DUARTE	CA	91010	LOS ANGELES	USA	Cancer Treatment Research	000	5	9/26/2022	NON-COMPETING CONTINUATION	$11,360
														Subtotal = $11,360

Issue Date FY: 2021 ( Subtotal = -$83,969 )
2021	2020	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	1500 DUARTE RD	DUARTE	CA	91010	LOS ANGELES	USA	Cancer Treatment Research	001	6	12/17/2020	SUPPLEMENT FOR EXPANSION	$0
2021	2020	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	1500 DUARTE RD	DUARTE	CA	91010	LOS ANGELES	USA	Cancer Treatment Research	000	6	11/27/2020	COMPETING CONTINUATION	$0
2021	2020	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	1500 DUARTE RD	DUARTE	CA	91010	LOS ANGELES	USA	Cancer Treatment Research	002	6	6/30/2021	COMPETING CONTINUATION	-$83,969
														Subtotal = -$83,969

Issue Date FY: 2020 ( Subtotal = $5,942,836 )
2020	2020	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	1500 DUARTE RD	DUARTE	CA	91010	LOS ANGELES	USA	Cancer Treatment Research	002	6	7/28/2020	COMPETING CONTINUATION	$0
2020	2020	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	1500 DUARTE RD	DUARTE	CA	91010	LOS ANGELES	USA	Cancer Treatment Research	001	6	5/1/2020	COMPETING CONTINUATION	$0
2020	2020	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	1500 DUARTE RD	DUARTE	CA	91010	LOS ANGELES	USA	Cancer Treatment Research	003	6	8/28/2020	SUPPLEMENT FOR EXPANSION	$207,400
2020	2020	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	1500 DUARTE RD	DUARTE	CA	91010	LOS ANGELES	USA	Cancer Treatment Research	000	6	4/21/2020	COMPETING CONTINUATION	$5,735,436
2020	2020	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	1500 DUARTE RD	DUARTE	CA	91010	LOS ANGELES	USA	Cancer Treatment Research	005	6	9/10/2020	COMPETING CONTINUATION	$548,292
2020	2019	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	1500 DUARTE RD	DUARTE	CA	91010	LOS ANGELES	USA	Cancer Treatment Research	004	5	9/10/2020	NON-COMPETING CONTINUATION	-$548,292
														Subtotal = $5,942,836

Issue Date FY: 2019 ( Subtotal = $1,582,668 )
2019	2019	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	1500 DUARTE RD	DUARTE	CA	91010	LOS ANGELES	USA	Cancer Treatment Research	002	5	8/22/2019	NON-COMPETING CONTINUATION	$0
2019	2019	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	1500 DUARTE RD	DUARTE	CA	91010	LOS ANGELES	USA	Cancer Treatment Research	000	5	3/1/2019	NON-COMPETING CONTINUATION	$1,582,668
2019	2019	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	1500 DUARTE RD	DUARTE	CA	91010	LOS ANGELES	USA	Cancer Treatment Research	001	5	3/5/2019	NON-COMPETING CONTINUATION	$0
														Subtotal = $1,582,668

Issue Date FY: 2018 ( Subtotal = $2,015,876 )
2018	2018	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	1500 DUARTE RD	DUARTE	CA	91010	LOS ANGELES	USA	Cancer Treatment Research	000	4	3/1/2018	NON-COMPETING CONTINUATION	$1,474,948
2018	2018	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	1500 DUARTE RD	DUARTE	CA	91010	LOS ANGELES	USA	Cancer Treatment Research	002	4	9/11/2018	NON-COMPETING CONTINUATION	$540,928
2018	2018	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	1500 DUARTE RD	DUARTE	CA	91010	LOS ANGELES	USA	Cancer Treatment Research	001	4	8/21/2018	NON-COMPETING CONTINUATION	$0
														Subtotal = $2,015,876

Issue Date FY: 2017 ( Subtotal = $0 )
2017	2016	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	1500 DUARTE RD	DUARTE	CA	91010	LOS ANGELES	USA	Cancer Treatment Research	000	3	3/1/2017	NON-COMPETING CONTINUATION	$0
2017	2016	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	1500 DUARTE RD	DUARTE	CA	91010	LOS ANGELES	USA	Cancer Treatment Research	001	3	3/1/2017	SUPPLEMENT FOR EXPANSION	$0
														Subtotal = $0

Issue Date FY: 2016 ( Subtotal = $1,916,982 )
2016	2016	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	1450 EAST DUARTE ROAD	DUARTE	CA	91010	LOS ANGELES	USA	Cancer Treatment Research	000	3	2/6/2016	NON-COMPETING CONTINUATION	$831,108
2016	2016	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	1450 EAST DUARTE ROAD	DUARTE	CA	91010	LOS ANGELES	USA	Cancer Treatment Research	002	3	9/19/2016	NON-COMPETING CONTINUATION	$214,734
2016	2016	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	1450 EAST DUARTE ROAD	DUARTE	CA	91010	LOS ANGELES	USA	Cancer Treatment Research	001	3	3/4/2016	SUPPLEMENT FOR EXPANSION	$871,140
														Subtotal = $1,916,982

Issue Date FY: 2015 ( Subtotal = $841,026 )
2015	2015	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	1450 EAST DUARTE ROAD	DUARTE	CA	91010	LOS ANGELES	USA	Cancer Treatment Research	000	2	2/27/2015	NON-COMPETING CONTINUATION	$841,026
														Subtotal = $841,026

Issue Date FY: 2014 ( Subtotal = $900,656 )
2014	2014	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	1450 EAST DUARTE ROAD	DUARTE	CA	91010	LOS ANGELES	USA	Cancer Treatment Research	001	1	9/8/2014	NEW	$50,000
2014	2014	BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE	1450 EAST DUARTE ROAD	DUARTE	CA	91010	LOS ANGELES	USA	Cancer Treatment Research	000	1	3/28/2014	NEW	$850,656
														Subtotal = $900,656

Grand Total All Awards = $17,918,626

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTN

Award Number: UM1CA186717

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/28/2014

PERIOD OF PERFORMANCE END DATE: 02/28/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer